Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Bigkahuna57on Jun 12, 2024 10:35pm
182 Views
Post# 36086323

RE:RE:RE:RE:Question for the Pharma Savvy

RE:RE:RE:RE:Question for the Pharma SavvyRef: $250M for 33% of the company?  I hope I misread that, and you meant as a buy-in with performance milestone payments for 1 single indication.  A total buyout for the entire portfolio and all future development of the galaxy of cancer indications at one time?  I don't think many would consider that b/c negotiations haven't run the full gammit of valuation possibilities, for the entire sum of cancer indications. 

I'm more inclinded to think once the 1st partnership and performance milestones are established, any future indications would be worth multiples, depending on the targeted cancer indication. And then hopefully bidding wars for new targeted indications.

Vulture capitalists buyout weak companies and sell them off in pieces based on "best" value and how each individual division/asset matches to a potential buyer.  The principal being that the sum total of the separate pieces are worth more than selling the weaker company's assets in 1 lump sum. Rarely do the entire stable of assets create maximum value to one buyer.  I will admit this is cancer we're talking about and I'd be shocked if only 1 Pharma was interested in the spectrum of possibilities that can be addressed by Ruvidar. 

I'm also betting that this new wave of laboratory testing of Ruvidar (as boosters or enhancements) to existing chemo drug treatments, is at the direction of Dr. Lbiati. Her most difficult challenge is getting an audience/1st meeting and the initial conversation has to have compelling potential. None more compelling than showing an enhancement of performance to "that particular company's" existing approved product.  

Interesting times. I'm enjoying reading about TLT's spectrum of lab testing and results using Ruvidar.

Thank you to everyone that contributes to the valuable details presented on this board, through your personal research and work experiences.

GLTA, BK
<< Previous
Bullboard Posts
Next >>